Hrt Financial LP Biomarin Pharmaceutical Inc Transaction History

Hrt Financial LP

$15.6 Billion
Q1 2024

A detailed history of Hrt Financial LP transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Hrt Financial LP holds 43,024 shares of BMRN stock, worth $3.54 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares

43,024

Previous 49,074 12.33%

Holding current value

$3.54 Million

Previous $4.73 Million 20.59%

% of portfolio

0.02%

Previous 0.03%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 13, 2024	SELL	$83.81 - $99.0 $507,050 - $598,950	-6,050 Reduced 12.33%	43,024 $3.76 Million
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $3.74 Million - $4.83 Million	49,074 New	49,074 $4.73 Million
Q1 2023 May 12, 2023	BUY	$87.74 - $117.27 $1.71 Million - $2.29 Million	19,515 New	19,515 $1.9 Million
Q2 2022 Aug 12, 2022	BUY	$71.48 - $86.85 $318,014 - $386,395	4,449 Added 151.53%	7,385 $611,000
Q1 2022 May 16, 2022	BUY	$74.28 - $92.69 $218,086 - $272,137	2,936 New	2,936 $226,000

Q3 2021 Nov 15, 2021	SELL	$74.77 - $85.47 $9.5 Million - $10.9 Million	-127,030 Closed	0 $0
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $9.59 Million - $10.8 Million	127,030 New	127,030 $10.6 Million
Q1 2021 May 17, 2021	SELL	$74.73 - $90.69 $9.84 Million - $11.9 Million	-131,636 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$72.61 - $90.2 $9.56 Million - $11.9 Million	131,636 New	131,636 $11.5 Million
Q4 2019 Feb 14, 2020	SELL	$64.27 - $86.37 $279,124 - $375,104	-4,343 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$67.4 - $85.11 $108,581 - $137,112	1,611 Added 58.97%	4,343 $292,000
Q2 2019 Aug 14, 2019	BUY	$80.35 - $93.9 $219,516 - $256,534	2,732 New	2,732 $233,000

Others Institutions Holding BMRN

# of Institutions

623

Shares Held

181M

Call Options Held

1.73M

Put Options Held

1.73M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $15.3B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Hrt Financial LP, based on Form 13F filings with the SEC.

News

Stay updated on Hrt Financial LP with notifications on news.

Account